When N-Boc-DL-phenylglycine (Boc-DL-Phg-OH, racemic tert-butoxycarbonyl-protected α-amino phenylacetic acid) is charged to a Boc-solid-phase peptide synthesis campaign, the primary process concern is not solubility but the α-carbon acidity that promotes oxazolone formation during carboxyl activation. On automated peptide synthesizers fitted with polytetrafluoroethylene reaction vessels of 0.1–0.5 mmol resin loading, the compound is typically dispensed as a 0.4–0.6 M DMF stock solution and metered at 2.5–4.0 molar equivalents relative to free amine on aminomethyl or MBHA resin. Activation with HBTU/HOBt/DIEA at 0.95–1.0 equivalent of coupling reagent relative to the protected amino acid is completed at 20–25 °C; pre-activation exceeding 90–120 s measurably increases diastereomeric impurity formation in the crude peptide. Coupling is run for 30–45 min, followed by resin filtration, DMF washes, and Boc removal with 50% TFA in DCM using two 30 min deprotection cycles. Batch-to-batch variance on manufacturing lines is most often traced to residual water in DMF above 500 ppm; proper drying over molecular sieves or substitution with NMP reduces incomplete couplings. Compliance documentation for this application does not reference a single pharmacopoeial monograph because Boc-DL-phenylglycine is a protected research intermediate; supplier certificates of analysis instead align to ISO 17025:2017 clause 7.8 reporting, with HPLC purity thresholds commonly set at ≥ 98.0% and racemic identity confirmed by chiral HPLC. Terminal product types from this process include research-scale phenylglycine-containing peptides, peptide amides, and ligand probes used in binding assays; such products are not intended for commercial human use unless subsequently purified and characterised under GMP. The following table summarises coupling parameter ranges in two activation regimes.

How Does Activation Chemistry Control Racemization in Solution-Phase Amide Coupling?

In solution-phase synthesis of N-protected phenylglycine amides and esters, the operational window is set by the acid-lability of the Boc group and the acidifying effect of the phenyl substituent on the α-proton. The compound is dissolved in anhydrous THF or 2-methyltetrahydrofuran and activated with isobutyl chloroformate at −18 to −10 °C in the presence of N-methylmorpholine at 1.05–1.15 equivalents relative to the carboxylic acid; the resulting mixed anhydride is then treated with the amine nucleophile at 0–5 °C, and the batch is gradually warmed to 20–25 °C over 2–4 h. The charging ratio for API intermediate manufacturing is generally 1.0–1.2 molar equivalents of Boc-DL-phenylglycine relative to the amine component, with the slight excess compensating for residual moisture and anhydride decomposition. In process development, EDC·HCl/HOBt in DCM or DMF provides an alternative activation route, but it carries a higher risk of N-acylurea by-product capture in the crystallised product if the carbodiimide loading exceeds 1.2 equivalents. Production-scale equipment for this step typically consists of glass-lined reactors of 50–500 L with bottom discharge, nitrogen blanket, and jacket temperature control of ±2 °C; addition of isobutyl chloroformate is rate-limited to keep the internal temperature below −10 °C. Workup includes quench with 1 M HCl, phase separation, brine wash, drying over sodium sulfate, and crystallisation from ethyl acetate/heptane 3:1 v/v to yield protected amino acid amides or esters. Compliance for this class of intermediate is typically linked to ICH Q11 starting material justification for peptide APIs, with residual solvent limits assessed under USP <467> and elemental impurities under ICH Q3D; a CoA issued under ISO 17025:2017 should identify assay by non-aqueous titration or HPLC and state the enantiomeric ratio. Terminal product types include N-Boc-phenylglycine amides, methyl and ethyl esters, and small peptide fragments used for medicinal chemistry and peptide isostere development. The process is incompatible with strongly nucleophilic bases such as aqueous sodium hydroxide at above +10 °C, which can deprotonate the α-carbon and cause irreversible racemization.

Enantiopure Boc-D-phenylglycine and Boc-L-phenylglycine are recovered from the racemate by diastereomeric salt formation rather than direct preferential crystallisation, because the free acid is not conglomerate-forming. The racemic Boc-DL-phenylglycine is dissolved in ethanol or 2-propanol at 40–50 °C at a solvent loading of 8–12 mL per gram of substrate; a chiral resolving base, such as (S)-(−)-α-methylbenzylamine or (R)-(+)-α-methylbenzylamine, is added at 0.45–0.55 molar equivalents, and the batch is cooled to 0–5 °C at a controlled rate of 10–15 °C/h. The precipitated diastereomeric salt is isolated on a Nutsche filter, reslurried in ethanol/water 3:1 v/v, and recrystallised until the salt meets the input chiral purity threshold for the subsequent acidification step. Liberation of the free acid is performed by partition between ethyl acetate and 1 M HCl at pH 2.0–2.5, followed by brine washing and concentration to a crystalline solid; the mother liquor containing the opposite enantiomer is recovered by salt hydrolysis and may be racemised or reused for continuity. Chiral HPLC equipment fitted with an amylose-based stationary phase and hexane/2-propanol/trifluoroacetic acid mobile phase is used to monitor enantiomeric ratio; acceptance is commonly set at ≥ 98.0% ee for peptide starting materials and ≥ 98.5% ee when the downstream is antibiotic side chain manufacture. The compliance framework for this operation falls under ICH Q7 Section 12.7 for recovery of materials and ISO 14644-1 Class 8 for non-sterile final filtration and drying; no dedicated pharmacopoeial monograph governs the resolved protected amino acid, so purchaser audit standards are typically drawn from ISO 9001:2015 clause 8.4 supplier quality systems. Terminal products from this process are the two enantiomers of N-Boc-phenylglycine, which enter peptide coupling or β-lactam routes as differentiated intermediates. Published data for this specific configuration is limited with respect to exact yield reproducibility across different resolving bases; kilogram-scale runs require laboratory verification of salt solubility and crystal habit before fixing the production recipe.

When Diastereomeric Salt Resolution Supplies the D-Phenylglycine Side Chain

The connection between Boc-DL-phenylglycine and β-lactam antibiotic synthesis runs through the D-phenylglycine fragment that acylates 6-aminopenicillanic acid (6-APA) or 7-aminodeacetoxycephalosporanic acid (7-ADCA). Resolved Boc-D-phenylglycine is first deprotected with 3.0–5.0 M HCl in dioxane or 1:1 v/v TFA/DCM at 20–25 °C for 2–6 h, producing D-phenylglycine hydrochloride after evaporation and trituration. In a typical ampicillin route, D-phenylglycine is converted to the acid chloride hydrochloride with phosphorus pentachloride or thionyl chloride, then added to a chilled aqueous acetone solution of 6-APA at 0–5 °C while pH is maintained at 6.5–7.5 with 1 M NaOH or ammonium hydroxide. The acylation ratio is kept at 1.0–1.3 molar equivalents of acylating agent relative to 6-APA to minimise residual β-lactam starting material while not over-acylating the amine; prolonged pH excursions above 8.0 trigger β-lactam ring opening and must be avoided by automated pH control. Cephalexin production follows an analogous route using 7-ADCA, where the same D-phenylglycine side chain is linked to the cephalosporin nucleus under pH-stat conditions. Terminal product types include ampicillin trihydrate and cephalexin monohydrate as final APIs, with release specifications governed by USP Ampicillin and Ph. Eur. Ampicillin monographs; upstream intermediates are controlled under ICH Q7 and supplier CoAs issued under ISO 17025:2017. The addition ratio of Boc-DL-phenylglycine into this supply chain is indirect: it enters as the racemic starting material, must be resolved as described above, and only the D-enantiomer after deprotection is active in β-lactam acylation. Residual N-Boc contamination in the side-chain feed is regarded as a critical process risk because tert-butoxycarbonyl deprotection releases isobutylene and carbon dioxide; incomplete deprotection can leave unreacted protected acid that acylation does not consume, contaminating the isolated API with hydrophobic impurities. Consequently, operators on production lines require a Boc-deprotection endpoint check by NMR or HPLC before the acylation vessel is charged.

Lipase-catalysed ester hydrolysis of Boc-DL-phenylglycine methyl or ethyl esters has been evaluated for producing enantiomerically enriched N-protected phenylglycine without chiral amine resolving agents. The free acid is first esterified with thionyl chloride in methanol or ethanol to give the racemic ester, which is then charged to a jacketed stirred reactor containing immobilized Candida antarctica lipase B on acrylic resin at an enzyme loading of 5–20 wt% relative to the ester substrate. Hydrolysis is conducted in aqueous phosphate buffer at pH 7.0–7.5 and 30–40 °C; the pH-stat pumps 0.5 M NaOH to neutralise the liberated carboxylic acid, and the reaction is arrested at 45–52% conversion to hold enantioselectivity above the acceptance threshold. The unreacted ester and the hydrolysed acid are then separated by extraction against ethyl acetate at pH 8.5–9.0, with the aqueous phase containing the N-protected amino acid and the organic phase retaining the ester. Equipment requirements include a pH-stat controller with deadband ±0.05 pH, a recirculating water bath with ±1 °C stability, and immobilized enzyme filtration through a 50 µm screen before reuse; batch-to-batch variance is driven by enzyme moisture, buffer ionic strength, and the degree of ester hydrolysis before arrest. Biocatalytic steps of this type are controlled as raw material transformations under ICH Q7 Section 7.3, while analytical release of enantiomeric purity uses chiral HPLC under ISO 17025:2017; no specific pharmacopoeial standard covers the racemic or resolved ester, so the commercial specification is usually negotiated against the downstream peptide synthesis tolerance for the undesired enantiomer. Terminal product types are chiral Boc-phenylglycine esters and acids, which serve as coupling intermediates for peptide and medicinal chemistry programmes. Published data for this specific substrate is limited; the operational ranges above are starting points that must be confirmed against the selected enzyme immobilisate and ester configuration before scale-up.

Analytical Reference Standards and Impurity Profiling in Peptide API Release

In quality-control laboratories supporting peptide APIs that contain phenylglycine residues, Boc-DL-phenylglycine is used as an external reference material for chromatographic system suitability and for identifying residual free acid or diastereomeric peptide impurities. Calibration solutions are prepared in acetonitrile/water 50:50 v/v at concentrations from 0.05 to 1.5 mg/mL, filtered through a 0.22 µm PTFE syringe filter, and injected onto a C18 column with UV detection at 210 nm and a flow rate of 1.0 mL/min. The method must resolve the racemic acid from the N-Boc-D-phenylglycine and N-Boc-L-phenylglycine peaks if a chiral screening method is used; achiral methods are not suitable for configuration-specific quality decisions. Reference material producers supplying this compound for analytical use operate under ISO 17034:2016, and the required homogeneity and stability studies follow ISO Guide 35:2017; method validation for the receiving laboratory is documented under ICH Q2(R1). The terminal product type here is not a formulated drug but a qualified reference standard kit used in release, stability, and impurity profiling workflows. This application is a shallow zone of use because the material is consumed in milligram quantities and the procedural requirements are well established.